Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Open Label, Controlled, Dose Ranging Study of Maxy-G34 as an Adjunct to TAC Chemotherapy in High-Risk Patients With Stage I, II, or IIIa Breast Cancer.

NCT00501332 is registered in ClinicalTrials.gov with Maxygen Holdings Ltd. as lead sponsor.

NCT NCT00501332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00501332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Open Label, Controlled, Dose Ranging Study of Maxy-G34 as an Adjunct to TAC Chemotherapy in High-Risk Patients With Stage I, II, or IIIa Breast Cancer.
Lead sponsor
Maxygen Holdings Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
July 31, 2007
Completion date
Not reported
Enrollment
30 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, chemotherapy-induced neutropenia